


Bill Studier, the T7 System, and COVID Vaccines









John Shanklin, Chair of Biology Brookhaven National Laboratory September 8, 2022

TRACKING THE **E** CORONAVIRUS

the scientific marvel that helps

E. coli is a common bacteria

that dwells in humans, other

warm-blooded animals and

some foods. Some forms can

cause illnesses such as diarrhea

enemy in T7, which kills the bac-

teria by infecting it and rapidly

replicating its own proteins.

But E. coli has a natural

In an exquisite piece of scientific subterfuge, Studier real-

ized that T7 could be tricked

into copying good kinds of pro-tein — like the kind that helps

The Brookhaven team eventu-

they had to learn how to clone

"Our group accomplished this

in 1983," Studier, 84 and retired,

in Pleasanton, California. "This

enabled the T7 expression sys-

tem, which has been widely

that no other lab had done.

fight human diseases.

and urinary tract infections.

convert DNA into proteins.

* A 1983 BNL FIND IS KEY

Research on obscure enzyme leads to an accidental breakthrough

BY CARL MACGOWAN

A4

Long before anyone knew anything about COVID-19, sci-

entists studying an obscure enzyme at Brookhaven National Laboratory stumbled upon one of the key building blocks of two vaccines that today are saving potentially millions of lives, Newsday has learned.

The discovery nearly four decades ago of the so-called T7 expression system by a Brookhaven team led by senior biophysicist F. William Studier initially was of little interest to the general public. But scientists quickly grasped it could be used to study molecules and develop cancer treatments - and pharmaceutical giants Pfizer and Moderna incorporated the process into the vaccines that so far have been used in more than 250 million injections in the United States.

And it was all an accident. Studier had no idea he would help to fight a deadly disease when he began studying a virus that infects E. coli, a bacteria known as the scourge of the agricultural industry. It was simply the kind of routine scientific research that he and others at the Upton lab conducted

every day. "He was just studying how the virus worked," said John Shanklin, chair of Brookhaven's copying genes of living things then just realized that he had, kind of, the puzzle pieces to put

something together that would be uniquely useful."

Brookhaven's research is one of the reasons Moderna and

Pfizer were able to manufacture quantities, and so much faster Rosenberg, the late John Dunn,

Brookhaven

National Laboratory

than what would have been possible previously, said Venki Ramakrishnan, a Nobel Prize-wingraduate student Barbara Mofning biologist with the Medical fatt and postdoctoral fellow Research Council Laboratory of Parichehre Davanloo. Molecular Biology in Cam-Their research involved studbridge, Great Britain. ies of molecular mysteries such as messenger RNA, or mRNA,

NEWSDAY EXCLUSIVE

Studier's 38-year-old discovery also will help those companies swiftly and efficiently develop new versions of the vaccine as the coronavirus mutates into different variants, he said. "It's a very powerful tool," Ramakrishnan said in a telephone interview. "Of course, a lot of things went into it, but I would say the Brookhaven element is an essential component of what is needed to make this vaccine. . . . It made something possible that would not have been possible before."

Roots in gene-cloning

Pfizer and Moderna, in separate emails to Newsday, acknowledged their vaccines used the technology pioneered by the Brookhaven lab. Both companies declined to comment further. The research leading to the

T7 expression system had its roots in the 1970s gene-cloning sired to have large amounts of." craze, when scientists around the world were looking into ally figured out how to redirect T7 toward using its powers for good instead of evil. But first biology department. "And he as small as cells and as large as sheep. the little varmint - something

Studier had been studying bacteriophage T7, a virus that infects E. coli, since his graduate

school days in the early 1960s. He continued the research at Brookhaven, where he worked their vaccines in such enormous with senior researcher Alan



F. William Studier, seen in 2004, and a team created a clone technique used in COVID-19 vaccines.

WHAT TO KNOW

The so-called T7 expression system was discovered by a Brookhaven team in 1983 and is a key component in the production of the coronavirus vaccine In an exquisite piece of scientific subterfuge, a senior BNL biophysicist realized that T7 could be tricked into copying good kinds of protein - like the kind that helps fight human diseases

■ BNL's 38-year-old dis-covery will help Pfizer and Moderna develop new versions of the vaccine as the coronavirus mutates into different variants

"It turned out by luck," Rosenberg said in a phone interview, used for making almost any pro-"that T7 had elements that if teins. As it happens, it also enyou put them together in the ables obtaining large amounts of right fashion, what you could mRNAs for vaccines." do is fashion a system to [cre-Studier said the result, nearly ate] large amounts of messen-40 years later, is enormously ger RNA or any protein you de-

satisfying "I feel very good that our early work is helping to save so many lives," he wrote.

Shanklin said the genius of Studier's discovery was that he found he could substitute the gene of any living thing in E. coli, and then by adding components of the T7 virus, "He could trick the E. coli into essentially copywrote in an email from his home ing only that one protein." The discovery revolution-

ized science by simplifying

things that once had been labo-

fight the COVID-19 virus.

quickly alter the vaccine formula to fight COVID-19 variants, "the cumulative effect of those two things is we'll save millions of lives worldwide," Shanklin said.

May 25, 2021



Karen McNulty Walsh

Brookhaven officials said lab's history.

"T7 is still the go-to system for biochemists everywhere," lab officials said in a news release.

nology.

"Your cell makes the protein for you, and then you get the immunity from the protein that you made vourself," Shanklin said.

Combined with the ability to

rious, Shanklin said "It just changed everything about the way everyone did everything," he said. "It made it really simple."

Speeds vaccine production

Studier's discovery is the most successful technology in the

Brookhaven once held patents to the system, but they expired in 2014, lab officials said. Over the 24-year patent period, the lab was paid \$70 million in royalties by hundreds of companies that used the tech-

The technique also helped to speed development of the Moderna and Pfizer vaccines by providing crucial shortcuts.

First, the technology enables swift mass production of the vaccines. Then, once injected into human arms, the mRNA in the vaccine prompts our own cells to manufacture a "spike" protein, which in turn sends our immune systems into action to

Seeding tomorrow's medical discoveries

To retain a technological edge, we must inspire a love of science in the young

BY VENKI RAMAKRISHNAN

Head to revolutionary applications many years, sometimes decades or even centuries

later. When Isaac Newton discovered his laws of motion, he certainly did not imagine that those very laws would be used to launch satellites 300 years later. When Michael Faraday discovered the laws of electromagnetism that make the generation of electricity possible, a British politician asked him what good it was, to which he is said to have replied, "Someday, sir, you can tax it." Even Faraday could not have imagined that 150 years later electricity would pervade almost every aspect of our lives. Even an everyday device like a smartphone is based on several Nobel Prize-winning discoveries.

If we want a society that remains at the forefront of technologies tomorrow, we have to continue to produce the scientists of tomorrow by inculcating in young people a love of science and how it works. This requires a serious commitment to science education from the earliest years. Science is not a rote collection of facts. It is a way of discovering truths about the natural world through observation and experiments, along with theories that help us interpret and understand

the results. We also have to support the basic science of today, which is the seed corn for the completely unpredictable technologies of tomorrow. Trying to pick winners or focusing just on short-term applications is a guarantee of small, incremental gains rather than real, technological revolutions.

I was reminded of this by the COVID-19 vaccines, which are widely said to have been developed at unprecedented speed, available less than a year after the pandemic broke out. In fact, these vaccines were built on decades of fundamental science, including discoveries made by F. William Studier and his colleague John Dunn at Brookhaven National Laboratory. While studying how T7, a virus, attacks the bacterium E. coli, they and their colleagues figured out how to make large quantities of any RNA or protein of

choice. Moderna and Pfizer, makers of today's mRNA COVID-19 vaccines, rely on Studier's approach, which uses genetic elements derived from T7 to produce the mRNA instructions for making coronavirus spike proteins. When those mRNAs are delivered to our cells, *our* cells make the corresponding spike proteins. Those spikes train our immune system to be ready to fight the real COVID-19 virus if we are exposed.

Meanwhile, Katalin Kariko at the University of Pennsylvania discovered that injected mRNA would normally be quickly destroyed because the cell senses it as coming from a virus. But unexpectedly, she discovered that it could evade the cell's response if one of the building blocks of the mRNA was synthetically modified.

Both Studier's T7 system to produce large amounts of mRNA and Kariko's discovery of the need to modify it were essential to produce the lifesaving mRNA vaccines we have today. Today, both Pfizer and Moderna make their mRNA using Studier's T7 system while feeding it the modified building blocks based on the one that Kariko first identified. The synthetically modified mRNA is stable in the cell and allows large amounts of the COVID-19 spike protein to be made.

In both cases, the research was begun in pursuit of pure knowledge — and the practical applications were quite unanticipated and came decades after the original findings.




Venki Ramakrishnan is a Nobel Prize-winning biologist at the MRC Laboratory of Molecular Biology in Cambridge, England.

Newsday



Biology basics: genetic and biochemical analysis

- We humans have about 25,000 genes.
- Bacteria (e.g., E. coli) have approx. 4,000 genes.
- Viruses are very simple, e.g., T7 has only 56 genes
- Viruses can't live independently; for instance, T7 virus infect E. coli cells and hijacks their cellular machinery to make new virus particles.
- New viruses fill the cells and burst them, allowing them to infect other cells.
- Studier decided to study T7 to understand a "simple" form of life.






Figuring out how T7 works


- Studier's first goal was to sequence the 40,000 base pairs of its DNA genome with BNL colleague John Dunn.
- The T7 genome was amongst the first to be decoded.



John Dunn




Genome Assembly







How do genes work?



Like lightbulbs, genes need to be turned on too




How does the T7 virus hijack E. coli?



T7 brings its RNA polymerase enzyme, which recognizes the on-switches i.e., promoters in its own DNA.



Using T7 polymerase/promoter to make any protein



- Biochemistry of human disease
- Increasing crop productivity
- Making cancer therapeutics
- Other life-saving drugs
- T7 elements are so powerful, Studier used them to make an E. coli system that can churn out proteins using genes from anywhere.
- Studier's T7 system has been used in over 220,000 published studies, with about 12,000 new ones being added every year


A recent topical example...


How COVID-19 Wreaks Havoc on Human Lungs

New structure shows how virus envelope protein hijacks cell-junction protein and promotes viral spread. Findings could speed the design of drugs to block severe effects of COVID-19.

- BNL team used Studier's T7 system to make PALS and E proteins
- First major study from the NYS-funded cryo-Electron Microscope helped us figure out how they interact
- The team also showed that virulence depends on the E-PALS protein interaction
- Details of this interaction provided a new target for the design of drugs to prevent the interaction and block viral spread (Pfizer and

a these





Krios Titan

ScienceDailv

Your source for the latest research new




Vaccines to fight the COVID pandemic

- Flu vaccines are made by amplifying the virus in eggs
- The virus is extracted, killed and its antigens purified and used as a vaccine
- The process scale-up can take up to a year
- Pfizer and Moderna used Bill's T7 system to make a new kind of COVID vaccine from spike protein mRNA instead of the virus







Using T7 to accelerate vaccine scale up




- Can make many kilograms of RNA in a single batch, enough to vaccinate millions of people
- Can change DNA sequence quickly to pivot to new variants
- Development in months instead of years



The J and J Vaccine is a Modified Adenovirus







Summary

 In what started off as a basic science project to understand the biology and genetics of a model virus, Bill Studier made astute observations that helped him solve how to make viral RNA and proteins for study by his group at BNL



Bill Studier, 2012

- In solving the problem of making proteins for his own studies he created a system that has powered biological advances, accelerating discoveries in biomedical research worldwide
- Application of his discoveries by Moderna and Pfizer in making the COVID-19 vaccine saved 140k deaths in the USA and over \$900B in healthcare costs in first 5 months of 2020*, (global estimates are approximately 1.1M lives and 10M hospitalizations)
- A pretty good return on investment for curiosity-driven basic science.
- Bravo Bill!!



* https://bit.ly/3jm0Eb2